Skip to content

Incidence of Major Complication in Case of Thoracic Aortic Aneurysm

Predicting Moderate Thoracic Aortic Aneurysm Evolution: a Longitudinal Study of Systemic Factors in Patients Free of Connective Tissue Disease. .

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05395598
Acronym
MOTAAR
Enrollment
320
Registered
2022-05-27
Start date
2024-04-18
Completion date
2031-10-01
Last updated
2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic Aortic Aneurysm

Keywords

Thoracic aortic aneurysm, Incidence, nocturnal hypertension, Sleep apnea

Brief summary

Thoracic aneurysm is a silent disease with a potential mid-term high risk of death or major complications. Few data are available on the real incidence of major complications in case of small and moderate thoracic aneurysm. Different factors are supposed to increase the risk of aortic enlargement as high blood pressure and sleep disorder breathing. The modality of imaging and clinical follow-up are well defined. In this prospective observational study, the aim to assess the incidence of of major complications during follow-up in a population of patients with a small or moderate thoracic aneurysm. The study will also try to identify systemic factors influencing aneurysm evolution.

Interventions

None listed

Sponsors

University Hospital, Lille
Lead SponsorOTHER
Santelys Association
CollaboratorOTHER
Région Nord-Pas de Calais, France
CollaboratorOTHER
Association de Cardiologie Nord-Pas de Calais
CollaboratorUNKNOWN

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Documentation of an aortic root aneurysm \> 40 mm * Agreement to participate to a longitudinal study and available for a 5 years follow-up

Exclusion criteria

* Presence of comorbidities or pathology with a prognosis of less than 1 year * Personal or family history of genetically documented elastic tissue disease or patient meeting the GAND clinical criteria suggestive of Marfan disease * High-grade mitra-aortic valve disease, even if asymptomatic * Unbalanced hypertension ≥ 180/110 mmHg * Aneurysm (regardless of thoracic or abdominal location) ≥ 50 mm * Aneurysm (regardless of thoracic or abdominal location) with documented progression of more than 5 mm over one year * History of aortic surgery or endovascular intervention and history of type B aortic dissection of medical treatment * Renal insufficiency on dialysis, or GFR\< 30 ml/mn (CKD-EPI)

Design outcomes

Primary

MeasureTime frameDescription
Occurrence within 5 years of inclusion of a major aortic evenduring the 5 years after inclusionThis composite end point is defined as the occurrence of: * Aneurysm-related death * Emergency surgery for threatened aortic rupture or aortic dissection * Scheduled surgery for aneurysmal dilatation of more than 5 mm over 1 year * Aneurysm progression exceeding 55 mm in diameter * Root surgery for management of symptomatic aortic valve disease (insufficiency or narrowing) of high grade defined by tight aortic narrowing (V Max≥4 m/s, mean gradient ≥40mmHg, and area ≤1cm² or severe aortic insufficiency (regurgitated volume≥60 ml, shortening fraction≥ 50%.

Secondary

MeasureTime frameDescription
Number of Participants with controlled blood pressure defined by ambulatory blood pressure measurementduring the 2 years after inclusionThe blood pressure measurement (averaged over 24 h)\<130/80 mmHg and nocturnal blood pressure ≤120/70 mmHg
Presence of sleep disorders defined by an 'Apnea Hypopnea Index and/or an Oxygen Desaturation Indexduring the 2 years after inclusionfor Apnea Hypopnea Index = ≥5 events per hour for Oxygen Desaturation Index = ≥5 events per hour
Occurrence during the 5 years after inclusion of a major cardiovascular eventduring the 5 years after inclusionThis composite criterion is defined by the occurrence of death from cardiovascular causes, myocardial infarction, stroke (ischemic or hemorrhagic), or hospitalization for heart failure

Countries

France

Contacts

CONTACTPascal DELSART, MD
pascal.DELSART@chru-Lille.fr0320445962
PRINCIPAL_INVESTIGATORPascal DELSART, MD

University Hospital, Lille

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 16, 2026